Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia. 2004 Aug;18(8): ...
Jun 17, 2004 · We initiated a prospective phase I/II trial using a modified protocol of adoptive immunotherapy to treat AML relapse post-transplant.
PDF | On Sep 1, 2004, Christoph Schmid and others published Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after ...
Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Schmid, C; Schleuning, M ...
Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation [2]. Christoph Schmid, M ...
In this narrative review, we explore the obstacles and opportunities of allogeneic stem cell transplantation in acute myeloid leukemia as well as the recent ...
Missing: ARAC, | Show results with:ARAC,
G-CSF use has been associated with later development of myelodysplastic syndromes/acute myelogenous leukemia (MDS/AML) in several clinical circumstances.
Missing: ARAC, recurrent
Nov 16, 2007 · The study evaluated the sequence of low-dose(ld)AraC for leukemic control (intensive chemotherapy for progressive disease only), transfusion of ...
Missing: recurrent | Show results with:recurrent
Feb 1, 2023 · In this paper, we summarize novel therapies for AML before, during, and after allo-HCT and review ongoing studies.
Jan 10, 2001 · Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem ...